xBiologix is a pre-seed start-up developing color biopsies to screen malignant
tumors for drug targets. Using color biopsies, clinicians can prescribe the right
drugs for each patient within days after surgery. Currently, more than 65% of
patients diagnosed with solid tumors do not respond to prescribed treatments,
primarily because predicting treatment response depends on simultaneously
visualizing dozens of tumor features. Monochrome biopsies only show one
feature at a time, color biopsies enable this critically important visualization.
Three in five people alive today will be diagnosed with a solid tumor in their
lifetime— nearly every family is directly affected by these cancers. Color biopsies
will change the trajectory of cancer treatment by cutting the number of failed
solid tumor treatments in half.
xBiologix is first to market with a new, patented synthetic biology that builds on
the 2022 Nobel Prize for click chemistry, enabling the unsurpassed advantages of
these color microscopy reagents in clinics. And our technology lets customers use
instruments many already own— making timely treatment decisions clinically,
financially and economically viable.
We all want more effective cancer treatments. The fastest way for us to start
helping real patients is to get our reagents into clinical trials for new cancer drugs.
Developing reagents for use in clinical trials will both generate revenue and help
the more than 1.2M patients who enroll in solid tumor trials annually. xBiologix
currently has opportunities for its reagents in three clinical trials. Drug developers
using xBiologix’s reagents benefit because our reagents screen for patients who
respond to their therapies, significantly improving clinical trial performance.
Patients benefit because they are matched with drugs that are more likely to be
effective. It’s a win-win, but to get started we need support from a few small
investors.
xBiologix expects to see potential exits as it grows from three to thirty
customers in 18-24 months— after closing its current $1.5M raise. Healthy margins
are projected to produce $10M in profit on $16M in revenue. Both strategic and
technology exits are possible in a three-to-five year timeframe. Strategic exits,
ranging from $50-$150M involve spatial biology company mergers as the $2B
market (TAM/2029) consolidates. A noteworthy technology exit recently occurred
when Johnson and Johnson purchased a small biotech company for $2.4B; and
Novartis agreed to pay $1.7B for services from a seed-stage company similar to
xBiologix in December 2025.
If you’re a mission-driven investor, xBiologix is a unique opportunity to change
the lives of the nearly 2M people diagnosed with solid tumor cancers in the US
every year by helping more patients get the therapy that works sooner, and by
helping promising new drugs reach the right patients faster.
Information Technology
Solutions
At a glance
Solid tumor, color biopsy
reagents for use in clinical
settings
Advantages
✓ 30+ colors per slide
✓ Results in 3-4 days
✓ No new instruments
✓ Personalizes treatment
Impacts
▫▫ Color biopsies
predict how
patients’ solid
tumors respond to
drugs
▫▫ Treatment
decisions can be
made in days, not
months
▫▫ Color biopsies
improve outcomes
by 35% or more
▫▫ Color reagent and
process costs as low
as monochrome
For more information
email:
investors@xbiololix.com
A Startup you’d be proud to support
xBiologix
Making Oncology Work
®
© 2026 xBiologix, Inc. All rights reserved.
2121 NE Jack London Street Suite 110
Corvallis Oregon 97330
xBiologix
®
Making Oncology Work